Together, Cleary and colleagues provided direct in vivo evidence showing that central inhibition of Nav1.8 was effective at normalizing breathing and behavioral abnormalities in a PTHS mouse model, further supporting the idea of Nav1.8 as a therapeutic target. Here, SCN10A is linked to Pitt-Hopkins syndrome.